" class="no-js "lang="en-US"> Brian Min - Medtech Alert
Thursday, December 12, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Brian Min

Brian Min

About Brian Min

  • B.A. from University of California, Berkeley
  • Ph.D. from University of California, Los Angeles
  • 25+ years of experience on biologics development and manufacturing
  • 10+ years experience of antibody discovery in Amgen
  • Experience from target identification/validation to market approval of biologics
  • Played a key role in development of 2 marketed novel biologics
  • Financial impact analysis of drug development and commercialization
  • Experience in IMPD and CTD preparation as well as interaction with regulatory agencies (EMA, FDA, etc.).
  • Led development and manufacturing of all biosimilars in Samsung Bioepis; Scale-up experience to 15,000L bioreactor
  • 6 marketed commercial products in US, EU and South Korea. Established GenScript ProBio.
  • Core team member that led formation for Samsung Bio companies through joint venture formations

Related Story

Diseases

 Avacta Announces AffyXell Expands Its Strategic Partnership With GenScript ProBio | Pharmtech Focus

Avacta Announces AffyXell Expands Its Strategic Partnership With GenScript ProBio

May 17 2022

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company developing innovative cancer therapies […]